Pfizer Reports Mixed Q1 2026 Results, Reaffirms 2026 Guidance Amid Pipeline Momentum
Event summary
- Pfizer reported Q1 2026 revenues of $14.5 billion, up 2% operationally Y/Y, with 22% growth in launched and acquired products.
- Adjusted diluted EPS of $0.75, down 18% Y/Y, reflecting non-recurrence of favorable 2025 adjustments and higher R&D spending.
- Reaffirmed 2026 guidance: revenues of $59.5–62.5 billion and adjusted diluted EPS of $2.80–3.00.
- Key product growth drivers: Padcev (+39%), Eliquis (+8%), Oncology biosimilars (+52%), and Nurtec ODT/Vydura (+41%).
- Strategic commercialization deal with Sciwind Biosciences for ecnoglutide in China, with up to $495M in potential milestone payments.
The big picture
Pfizer's Q1 2026 results reflect a mixed performance, with operational revenue growth offset by declines in COVID-19 product revenues and higher R&D spending. The company's reaffirmation of 2026 guidance underscores confidence in its pipeline and commercial strategy, particularly in oncology and obesity. The strategic deal with Sciwind Biosciences highlights Pfizer's focus on expanding its footprint in high-growth markets like China. The broader industry context includes increasing competition from biosimilars and generic entrants, as well as regulatory pressures on drug pricing and access.
What we're watching
- Pipeline Execution
- Whether Pfizer can sustain momentum in oncology and obesity pipelines following positive Phase 3 results for Braftovi, Elrexfio, and Talzenna.
- Commercial Strategy
- The impact of organizational changes in the Global Biopharmaceuticals Business on product portfolio performance.
- Regulatory Dynamics
- The pace at which Pfizer secures additional regulatory approvals for key products like Padcev and Hympavzi.
Related topics